Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 2Unknown 1Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other neoplasm 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Rectal Neoplasms 1Radiation Injuries 1Multiple Myeloma 1Multiple Chronic Conditions 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1Hematologic Neoplasms 1Fatigue 1Cognitive Dysfunction 1Carcinoma, Basal Cell 1Breast Neoplasms 1Breast Neoplasm Female 1Brain Neoplasms 1

Interventions

Dexamethasone 64Cyclophosphamide 40Bortezomib 37Melphalan 24Lenalidomide 23Thalidomide 17pomalidomide 16fludarabine 12daratumumab 11carfilzomib 10Filgrastim 8Doxorubicin 8Busulfan 6Prednisone 5Peripheral Blood Stem Cell Transplantation 5Bendamustine Hydrochloride 5selinexor 4sargramostim 4isatuximab 4fludarabine phosphate 4Surveys and Questionnaires 4Etoposide 4Clarithromycin 4Calcium Dobesilate 4liposomal doxorubicin 3ixazomib 3Radiotherapy 3Neoadjuvant Therapy 3Mycophenolic Acid 3Methylprednisolone 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Multiple Myeloma × Patient Reported Outcome Measures × Clear all
NCT04663100 2023-12-04

Oral Adherence in Hematological Oncology Agents and Impact on Comorbid Therapy Adherence

University of Tennessee

Phase NA Unknown
30 enrolled
LymphoidMyeloidOther hematologic neoplasmOther neoplasmPlasma cell

Multiple Chronic Conditions, Leukemia, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡